The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Predicting thrombocytopenia as a result of ruxolitinib treatment in MF
Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, discusses a retrospective study which aimed to identify clinical and genetic variables predictive of increased risk of ruxolitinib treatment-induced thrombocytopenia in patients with myelofibrosis (MF). The key driver and predictor of thrombocytopenia was baseline platelet count at initiation of ruxolitinib treatment, and this research highlights the potential to identify patients who are at highest risk for this treatment-related adverse event (AE). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Celgene/BMS, Cogent, Incyte, Abbvie, Imago, Novartis, PharmaEssentia, CTI Biopharma, MorphoSys, GSK, Karyopharm
Research Funding: MorphoSys, BMS, Protagonist Therapeutics, Janssen
Advisory Board: Dark Blue Therapeutics
